medullary thyroid cancer and glp 1 GLP-1 Receptor Agonists Risk Rodent Data and FDA Warning Do GLP-1 drugs cause cancer?

In research discussions, it is commonly grouped with ghrelin receptor agonists and growth hormone-releasing peptides, but it is often presented as a more selective compound

However, older GLP-1 medications like dulaglutide and liraglutide still produce clinically meaningful outcomes, often with extensive real-world experience and well-characterized safety profiles

Other research highlights: 30% of GLP-1 users tested positive for SIBO or IMO even after accounting for diabetes (5) GLP-1 medicines caused microbiome changes and altered metabolism in mice (6) GLP-1 medicines tested in humans only had noticeable microbiome changes by 48 weeks (7) Despite not necessarily having slower gut motility, one study found that 88.9% of obese patients had SIBO (8) A meta analysis of people with IBS symptoms, found that up to 78% of people had SIBO, many of whom were undiagnosed (9) Overall, Sun and colleagues (1) could not prove a mechanistic link between GLP-1 medications and SIBO, however they did find that SIBO was twice as likely in GLP-1 users

How often we test depends on the patients health and how they react to treatment

Still Deciding

Here are some of the nutrients found in garlic according to the USDA